A comparative review of adenovirus A12 and C5 oncogenes

IF 5.7 2区医学 Q1 VIROLOGY

Current opinion in virology Pub Date : 2024-06-11 DOI:10.1016/j.coviro.2024.101413

Luca D Bertzbach , Wing-Hang Ip , Konstantin von Stromberg , Thomas Dobner , Roger J Grand

{"title":"A comparative review of adenovirus A12 and C5 oncogenes","authors":"Luca D Bertzbach , Wing-Hang Ip , Konstantin von Stromberg , Thomas Dobner , Roger J Grand","doi":"10.1016/j.coviro.2024.101413","DOIUrl":null,"url":null,"abstract":"<div><p>Oncogenic viruses contribute to 15% of global human cancers. To achieve that, virus-encoded oncoproteins deregulate cellular transcription, antagonize common cellular pathways, and thus drive cell transformation. Notably, adenoviruses were the first human viruses proven to induce cancers in diverse animal models. Over the past decades, human adenovirus (HAdV)-mediated oncogenic transformation has been pivotal in deciphering underlying molecular mechanisms. Key adenovirus oncoproteins, encoded in early regions 1 (E1) and 4 (E4), co-ordinate these processes. Among the different adenovirus species, the most extensively studied HAdV-C5 displays lower oncogenicity than HAdV-A12. A complete understanding of the different HAdV-A12 and HAdV-C5 oncoproteins in virus-mediated cell transformation, as summarized here, is relevant for adenovirus research and offers broader insights into viral transformation and oncogenesis.</p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":"67 ","pages":"Article 101413"},"PeriodicalIF":5.7000,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1879625724000270/pdfft?md5=b1c8568f6544b889bae01e107ab80485&pid=1-s2.0-S1879625724000270-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in virology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1879625724000270","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VIROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Oncogenic viruses contribute to 15% of global human cancers. To achieve that, virus-encoded oncoproteins deregulate cellular transcription, antagonize common cellular pathways, and thus drive cell transformation. Notably, adenoviruses were the first human viruses proven to induce cancers in diverse animal models. Over the past decades, human adenovirus (HAdV)-mediated oncogenic transformation has been pivotal in deciphering underlying molecular mechanisms. Key adenovirus oncoproteins, encoded in early regions 1 (E1) and 4 (E4), co-ordinate these processes. Among the different adenovirus species, the most extensively studied HAdV-C5 displays lower oncogenicity than HAdV-A12. A complete understanding of the different HAdV-A12 and HAdV-C5 oncoproteins in virus-mediated cell transformation, as summarized here, is relevant for adenovirus research and offers broader insights into viral transformation and oncogenesis.

查看原文本刊更多论文

腺病毒 A12 和 C5 致癌基因的比较研究。

致癌病毒导致全球 15%的人类癌症。为了实现这一目标，病毒编码的癌蛋白会干扰细胞转录，拮抗常见的细胞通路，从而推动细胞转化。值得注意的是，腺病毒是第一个被证实能在不同动物模型中诱发癌症的人类病毒。过去几十年来，人类腺病毒（HAdV）介导的致癌转化在破译潜在分子机制方面发挥了关键作用。早期区 1（E1）和 4（E4）编码的关键腺病毒癌蛋白协调了这些过程。在不同种类的腺病毒中，研究最广泛的 HAdV-C5 比 HAdV-A12 的致癌率低。本文总结的对不同的 HAdV-A12 和 HAdV-C5 癌蛋白在病毒介导的细胞转化过程中的作用的全面了解与腺病毒研究息息相关，并为病毒转化和致癌提供了更广泛的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current opinion in virology VIROLOGY-

CiteScore

11.80

自引率

5.10%

发文量

审稿时长

83 days

期刊介绍： Current Opinion in Virology (COVIRO) is a systematic review journal that aims to provide specialists with a unique and educational platform to keep up to date with the expanding volume of information published in the field of virology. It publishes 6 issues per year covering the following 11 sections, each of which is reviewed once a year: Emerging viruses: interspecies transmission; Viral immunology; Viral pathogenesis; Preventive and therapeutic vaccines; Antiviral strategies; Virus structure and expression; Animal models for viral diseases; Engineering for viral resistance; Viruses and cancer; Virus vector interactions. There is also a section that changes every year to reflect hot topics in the field.